Barclays has initiated coverage on Hims & Hers Health Inc (HIMS) with an Overweight rating, marking its first assessment of the company. This rating reflects Barclays' analysis of Hims & Hers' business model, industry dynamics, and growth prospects.
Hims & Hers operates a telehealth consultation platform, providing access to a network of licensed healthcare professionals. The company, headquartered in San Francisco, California, employs 1,637 full-time staff and went public on September 9, 2019. Its platform offers treatments for various chronic conditions, including sexual health, hair loss, dermatology, mental health, and weight loss.
As of December 8, 2025, Hims & Hers trades at $37.19, with a market capitalization of $8.9 billion. The company's price-to-earnings ratio stands at 66.56, with a trailing twelve months earnings per share of 0.53. Upcoming earnings reports are scheduled for August 3, 2026, with earnings per share estimated at $0.17 and revenue expected at $672.0 million.
Analyst ratings provide valuable insight but are based on assumptions that may not always hold true. As such, they should be considered alongside company fundamentals and broader market conditions. Analyst opinions may evolve as new information emerges, and different analysts can hold varying views on the same stock.